Related Experiment Videos
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
A F Carpentier1, L Chen, F Maltonti
1Fédération de neurologie Mazarin et INSERM U 495, Hôpital de la Pitié-Salpêtrière, Paris, France.
Abstract:
Phosphorothioate oligodeoxynucleotides with CpG motifs (CpG-ODNs) activate various immune cell subsets and induce production of numerous cytokines. To evaluate whether CpG-ODNs can induce rejection of established malignant tumor, A/J mice were challenged by the s.c. implantation of a syngenic neuroblastoma cell line (neuro2a) and subsequently injected with CpG-ODNs in the vicinity of the tumor. Daily injections of 10 microg CpG-ODNs for 15 days seemed to be the most potent regimen, leading to the eradication of 5-mm-diameter tumors in one-half of the animals and a significant tumor growth inhibition when compared with controls (88% reduction volume; P<0.001). CpG-ODN-cured animals were further protected against a new tumor challenge. The antitumoral effect of CpG-ODNs was dependent on CpG motifs, and natural killer cells seemed to play a critical role in tumor rejection. We conclude that immunostimulatory CpG-ODNs may induce the rejection of established tumors and warrant further evaluation as a potential immunotherapeutic agent.
Insights
Immunostimulatory CpG oligodeoxynucleotides (CpG-ODNs) eradicated established neuroblastomas in mice. These CpG-ODNs show potential as an immunotherapeutic agent for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- CpG-ODNs activate immune cells and cytokines.
- CpG-ODNs are being investigated for cancer immunotherapy.
Purpose of the Study:
- To determine if CpG-ODNs can induce rejection of established tumors.
- To evaluate the efficacy of CpG-ODNs in a murine neuroblastoma model.
Main Methods:
- A/J mice received s.c. implantation of neuroblastoma cells.
- Mice were subsequently treated with daily injections of CpG-ODNs near the tumor.
- Tumor volume and rejection were monitored over time.
Main Results:
- Daily CpG-ODN injections eradicated 5-mm tumors in 50% of mice.
- Significant tumor growth inhibition (88% reduction) was observed (P<0.001).
- Treated mice showed protection against subsequent tumor challenges, indicating immunological memory.
Conclusions:
- CpG-ODNs can induce rejection of established neuroblastoma tumors.
- The anti-tumoral effect relies on CpG motifs and natural killer cell activity.
- CpG-ODNs represent a promising candidate for further cancer immunotherapy development.